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MaBACKGROUND Transcutaneous low-level tragus electrical stimulation (LLTS) suppresses atrial ﬁbrillation (AF) in
canines.
OBJECTIVES This study examined the antiarrhythmic and anti-inﬂammatory effects of LLTS in humans.
METHODS Patients with paroxysmal AF who presented for AF ablation were randomized to either 1 h of LLTS (n ¼ 20)
or sham control (n ¼ 20). Attaching a ﬂat metal clip onto the tragus produced LLTS (20 Hz) in the right ear (50% lower
than the voltage slowing the sinus rate). Under general anesthesia, AF was induced by burst atrial pacing at baseline and
after 1 h of LLTS or sham treatment. Blood samples from the coronary sinus and the femoral vein were collected at those
time points and then analyzed for inﬂammatory cytokines, including tumor necrosis factor alpha and C-reactive protein,
using a multiplex immunoassay.
RESULTS There were no differences in baseline characteristics between the 2 groups. Pacing-induced AF duration
decreased signiﬁcantly by6.3 1.9min comparedwith baseline in the LLTS group, but not in the control subjects (p¼0.002
for comparison between groups). AF cycle length increased signiﬁcantly from baseline by 28.8 6.5 ms in the LLTS group,
but not in control subjects (p ¼ 0.0002 for comparison between groups). Systemic (femoral vein) but not coronary sinus
tumor necrosis factor (TNF)-alpha and C-reactive protein levels decreased signiﬁcantly only in the LLTS group.
CONCLUSIONS LLTS suppresses AF and decreases inﬂammatory cytokines in patients with paroxysmal AF. Our results
support the emerging paradigm of neuromodulation to treat AF. (J Am Coll Cardiol 2015;65:867–75) © 2015 by the
American College of Cardiology Foundation.T he most common cardiac arrhythmia, atrialﬁbrillation (AF), is associated with signiﬁcantcardiovascular morbidity and mortality (1,2).
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ABBR EV I A T I ON S
AND ACRONYMS
AERP = atrial effective
refractory period
AF = atrial ﬁbrillation
AH = atrial-His
AV = atrioventricular
CANS = cardiac autonomic
nervous system
CRP = C-reactive protein
GP = ganglionated plexi
HF = heart failure
IL = interleukin
LLTS = low-level tragus
stimulation
LLVNS = low-level vagus
nerve stimulation
TNF = tumor necrosis factor
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868AF) is disappointing (event-free survival
<50% at 5 years) (4,5). As the population
ages, the AF population in the United States
is expected to reach 15 million by 2050 (6),
leading to a quest for alternative nonpharma-
cological, nonablative therapies for managing
patients with drug-refractory AF.SEE PAGE 876Neuromodulation is a novel therapy that
has been used successfully in various dis-
eases, including epilepsy (7) and heart failure
(HF) (8). We (9–13) and other investigators
(14) have shown that low-level cervical vagus
nerve stimulation (LLVNS), at voltages sub-
stantially below that associated with slowing
the sinus rate or atrioventricular (AV) nodal
conduction, signiﬁcantly suppresses AF in-
ducibility and shortens AF duration. Morerecently, we demonstrated in canines that
AF inducibility was suppressed by LLVNS using a
completely noninvasive approach by transcutaneous
low-level stimulation of the tragus (LLTS), the ante-
rior protuberance of the ear, where the auricular
branch of the vagus nerve is accessible (15). In the
present study, we evaluated the antiarrhythmic ef-
fects of 1-h LLTS in patients referred for catheter
ablation of paroxysmal AF. In addition, we examined
the anti-inﬂammatory effects of LLTS in these
patients.
METHODS
STUDY POPULATION. Patients with paroxysmal AF
referred to the electrophysiological laboratory for AF
ablation were eligible for enrollment. Patients were
excluded if they had left ventricular dysfunction
(deﬁned as left ventricular ejection fraction <40%),
signiﬁcant valvular disorder (i.e., prosthetic valve or
hemodynamically relevant valvular diseases), or
recent (<6 months) stroke. All patients underwent
baseline transthoracic and transesophageal echocar-
diography within 2 days prior to ablation. Antiar-
rhythmic medications were discontinued 5 days
before the procedure except amiodarone, which was
discontinued for at least 6 weeks. All patients received
pre-procedure anticoagulation with either warfarin,
to maintain an international normalized ratio be-
tween 2.0 and 3.0, or a new oral anticoagulant agent.
Warfarin was continued throughout the procedure,
whereas new oral anticoagulant agents were dis-
continued for 24 h pre-procedure. The study was
approved by the Institutional Review Board of the
University of Oklahoma Health Sciences Center. Afterproviding written informed consent, patients were
randomized to either LLTS for 1 h or sham LLTS
(control group).
EXPERIMENTAL PROTOCOL. Our laboratory routinely
performs the ablation procedure under general
anesthesia, using desﬂurane, vecuronium, and pro-
pofol. Before induction of general anesthesia, incre-
mental voltages were applied to the right tragus
(20 Hz, 1-ms square wave) through a Grass S88 stim-
ulator (Natus Neurology Incorporated, Warwick,
Rhode Island) connected to a stimulus isolation unit,
until the patient experienced discomfort. The dis-
comfort threshold was deﬁned as the lowest voltage
that resulted in any discomfort at the stimulation site.
After induction of general anesthesia, sheaths were
inserted in both femoral veins and coronary sinus. An
octapolar catheter was positioned at the His bundle
to monitor the atrial-His (AH) interval and a duo-
decapolar catheter was positioned in the coronary
sinus for atrial pacing. In the baseline state, the atrial
effective refractory period (AERP) was measured us-
ing programmed stimulation (S1-S1 ¼ 600 ms) at 10
diastolic threshold from the right atrial appendage
and the distal coronary sinus electrodes using 10 ms
S1-S2 decrements. Subsequently, burst atrial pacing
(cycle length decreasing from 250 ms to 200 ms) was
delivered through the coronary sinus catheter to
induce AF. This process was repeated until AF was
induced. AF inducibility, deﬁned as the number of
attempts required to induce AF, was recorded, as was
the duration of AF induced by burst atrial pacing. The
AF atrial cycle length was determined manually by
averaging 30 consecutive beats at a paper speed
100 mm/s, using screen calipers, as previously des-
cribed (16). Additionally, interelectrogram intervals
of <100 ms and continuous electrical activity were
counted as a single interval (16).
After acquiring the baseline parameters, LLTS or
sham treatment was initiated, regardless of AF
continuation (Figure 1A). Stimulation of the right ear
tragus was accomplished by attaching a ﬂat metal clip
onto the tragus, which served as the cathode, with
another clip at an adjacent site for the anode
(Figure 1B). Incremental voltages were applied to the
tragus (20 Hz, 1-ms duration, square wave) using a
Grass S88 stimulator until slowing of the sinus rate or
AV nodal conduction (AH prolongation) was achieved
(Figure 2). As soon as the sinus rate decreased and/or
the AH interval prolonged, stimulation was turned off
to avoid excessive bradycardia and/or heart block.
The lowest voltage to slow the sinus rate or prolong
the AH interval was deﬁned as the threshold for
setting the LLTS in each patient. LLTS was set at 50%
FIGURE 1 Study Protocol
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(A) Following the ﬁrst induction of atrial ﬁbrillation (AF), the groups underwent low-level electrical stimulation of the auricular branch of the
right vagus nerve at the tragus (LLTS) or a sham procedure for 1 h, followed by a second round of AF induction. (B) To achieve electrical
stimulation, a ﬂat metal clip was attached to the right tragus (dashed circle), which served as the cathode. Another clip on the ear lobe served
as the anode. LLTS ¼ low-level tragus stimulation.
FIGURE 2 Voltage Threshold for Heart Rate Slowing
(A) Before stimulation, sinus cycle length is 900 ms. (B) During stimulation at 20 V
(note stimulation artifact), there is an increase in the sinus cycle length to 930 ms.
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869below the voltage required to slow the sinus rate or
prolong the AH interval. In the experimental group,
LLTS was applied continuously for 1 h; in the control
group, the threshold was measured but no LLTS was
delivered. To prevent inadvertent supra-threshold
vagus nerve stimulation, the sinus rate and AH
interval were monitored continuously to ensure
that they were not altered by LLTS. The bispectral
index was continuously monitored, too, during the
procedure. The bispectral index was maintained be-
tween 40 and 60 during the maintenance phase of
general anesthesia. During the 1-h period of LLTS or
sham stimulation, transseptal puncture and electro-
anatomical mapping, but not ablation, were per-
formed. If the patient remained in AF at the end of
the hour, cardioversion was performed to restore
sinus rhythm. Within 5 min following the end of the
LLTS application, programmed stimulation and burst
atrial pacing were repeated using the same protocol
as before, to measure the AERP and induce AF,
respectively. Figure 1A illustrates the study protocol.
During baseline sinus rhythm, 5 ml of blood were
simultaneously obtained from the peripheral femoral
venous sheath (systemic sample) and the coronary
sinus sheath (cardiac sample). Simultaneous cardiac
and systemic samples were drawn again following 1 h
of LLTS or sham treatment (Figure 1A). For each blood
draw, the ﬁrst 10 ml were discarded, and the blood
was immediately transferred into tubes containing no
anticoagulant agent. After incubation in an upright
position at room temperature for 45 min to allow
clotting, the blood was centrifuged for 15 min at
2,000 g to obtain serum. Patients’ serum was savedfrozen at –80 C and processed in batches of 6 to 8.
The investigators performing the biomarker assays
were blinded to group assignment. Pro-inﬂammatory
cytokines, including tumor necrosis factor (TNF)–
alpha, C-reactive protein (CRP), interleukin (IL)-6,
and IL-10 were measured using a commercially
available assay analyzed on a ﬂow cytometer (multi-
plex assay; R&D Systems, Minneapolis, Minnesota).
TABLE 1 Baseline Patient Characteristics
LLTS Group
(n ¼ 20)
Control Group
(n ¼ 20) p Value
Age, yrs 60.9  7.8 62.9  9.8 0.48
Male 15 (75) 11 (55) 0.18
Duration of AF, yrs 6.6  4.9 5.5  4.3 0.48
Hypertension 15 (75) 15 (75) 1.00
Diabetes 1 (5) 5 (25) 0.08
Coronary artery disease 3 (15) 4 (20) 0.68
Obstructive sleep apnea 8 (40) 7 (35) 0.74
Left ventricular ejection fraction, % 61.7  7.3 60.8  6.1 0.66
Mean CHA2DS2-VASc score 1.5  0.9 2.2  1.3 0.06
CHA2DS2-VASc score 0.43
0 3 (15) 2 (10)
1 7 (35) 4 (20)
$2 10 (50) 14 (70)
Beta-blockers 11 (55) 12 (60) 0.75
ACE-I/ARB 7 (35) 11 (55) 0.20
Statin 6 (30) 8 (40) 0.51
New oral anticoagulant agents 12 (60) 15 (75) 0.31
Amiodarone 1 (5) 1 (5) 1.00
Other antiarrhythmic agents 12 (60) 14 (70) 0.49
Left atrial diameter, mm 42.5  9.1 43.3  6.9 0.77
Left atrial volume index, ml/m2 27.7  12.9 23.9  6.3 0.46
Left ventricular hypertrophy 13 (65) 14 (70) 0.74
Heart rate, beats/min 63.1  13.0 63.8  10.7 0.86
AH interval, ms 99.1  30.1 99.5  30.9 0.97
Direct current cardioversion 11 (55) 9 (45) 0.75
Discomfort threshold, V 29.1  10.4 28.3  9.0 0.87
Threshold for slowing heart rate, V 39.8  25.7 33.5  20.2 0.42
Values are mean  SD or n (%).
ACE-I ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; AH ¼ atrial-His;
ARB ¼ angiotensin receptor blocker; CHA2DS2-VASc ¼ age, congestive heart failure history,
hypertension history, stroke/transient ischemic attack/thromboembolism history, vascular disease
history, diabetes mellitus; LLTS ¼ low-level tragus stimulation.
TABLE 2 Electrophy
AF duration, min
AF cycle length, ms
Number of attempts,
median (interqua
range)
Minimum, maximum
RA AERP, ms
CS AERP, ms
Values are mean  SD unle
LLTS or sham procedure b
AERP ¼ atrial effective
Table 1.
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870All immunoassays were run in duplicate and read
according to manufacturer’s instructions.
STATISTICAL ANALYSIS. Data are presented as mean
 SD or percentages for continuous and catego-
rical variables, respectively. Comparisons in baselinesiologic Changes
LLTS Group (n ¼ 20) Control Group (n ¼ 20)
p Value*Baseline 1 h Baseline 1 h
16.7  6.2 10.4  5.2 17.1  5.7 18.5  5.6 0.002
189.1  37.6 217.9  33.0 200.6  42.3 191.9  49.1 0.0002
rtile
2 (1, 4) 4 (2, 6) 2 (1, 4) 1 (1, 2) 0.005
(1, 10) (1, 15) (1, 10) (1, 6)
222.3  31.1 232.3  31.1 236.4  46.5 227.8  43.0 0.04
222.7  41.0 230.8  41.0 253.3  53.7 240.7  50.6 0.04
ss otherwise indicated. *Comparison of the change in each parameter before and after
etween the 2 groups.
refractory period; CS ¼ coronary sinus; RA ¼ right atrial; other abbreviations as incharacteristics between groups were performed using
Student t test or chi-square test for continuous and
categorical variables, respectively. The differences in
burst atrial pacing-induced AF duration, number of
attempts, AERP, and inﬂammatory cytokines before
and after 1 h of LLTS or sham treatment were
compared between the groups with 2-way analysis
of variance. The analysis of variance modeling as-
sumptions were evaluated by plotting the residuals
by the predicted values (for the constant variance
assumption) and comparing the normal QQ plot with
the QQ plot of the residuals (for the normality
assumption). The assumptions of constant variance
and normality were reasonable for all analysis of
variance models based on the residual plots. The
difference in AF recurrence at follow-up between
the 2 groups was evaluated using the log-rank test.
Statistical signiﬁcance was declared at p < 0.05. All
statistical analyseswere performed using SAS software
(version 9.2, SAS Institute, Inc., Cary, North Carolina).
Based on experimental data (11), the present study
was powered to detect a 50% reduction in the dura-
tion of burst atrial pacing-induced AF after LLTS
versus in control subjects. A sample size of 40 pa-
tients (20 in each group) would provide at least 80%
power to detect this difference, at a 2-sided signiﬁ-
cance alpha level of 0.05.
RESULTS
We randomized 40 patients to either LLTS (n ¼ 20) or
sham control (n ¼ 20) groups. No statistically signiﬁ-
cant differences were observed in the baseline clinical
and echocardiographic characteristics between the
2 groups (Table 1); the discomfort threshold and
threshold for slowing the sinus rate or AV conduction
were also similar. During threshold determination,
the sinus rate decreased by 2.6  1.0 beats/min in the
LLTS group and by 2.7  1.3 in the control group. The
AH interval increased by 1.4  0.5 ms in the LLTS
group and by 1.5  0.5 ms in the control group. There
was no difference in the subtle changes of sinus rate
and AH interval between the 2 groups. During LLTS or
sham stimulation, there was no appreciable effect on
either the sinus rate or AH interval. Under general
anesthesia, we found no change in bispectral index
levels when LLTS was applied, indicating no effect of
LLTS on level of awareness.
Summarized in Table 2, there were no statistically
signiﬁcant differences in the baseline electrophysio-
logical parameters between the 2 groups. AF was
inducible in all but 1 patient in whom, after LLTS, AF
was not inducible after 15 attempts. Pacing-induced
AF duration decreased signiﬁcantly by 6.3  1.9 min
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Stavrakis, S. et al. J Am Coll Cardiol. 2015; 65(9):867–75.
This study examined the antiarrhythmic and anti-inﬂammatory effects of low-level electrical stimulation of the auricular branch of the right
vagus nerve at the tragus (LLTS) in patients referred for atrial ﬁbrillation (AF) ablation. We demonstrated for the ﬁrst time in humans that
LLTS compared with control (sham) stimulation (A) decreased AF duration and (B) suppressed inﬂammatory cytokines. LLTS ¼ low- level
tragus stimulation; TNF ¼ tumor necrosis factor.
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871in the LLTS group versus baseline levels and increased
by 1.4  1.8 min in the control group (between-group
comparison p ¼ 0.002; Central Illustration). Likewise,
pacing-induced AF cycle length increased signiﬁ-
cantly (28.8  6.5 ms) in the LLTS group com-
pared with baseline, but decreased (8.7  6.5 ms)
in the control group (between-group comparison
p ¼ 0.0002) (Figure 3). More attempts were required to
induce AF in the LLTS group compared with baseline,
whereas fewer attempts were required in the control
group compared with baseline (LLTS: 2 attemptsFIGURE 3 Effect of LLTS on Cycle Length
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There was a signiﬁcant increase in AF cycle length compared
with baseline in the LLTS group, but not in the control group.
Abbreviations as in Figure 1.before vs. 4 attempts after; control: 2 attempts before
vs. 1 attempt after; between-group comparison
p ¼ 0.005). The AERP at the right atrium and the distal
coronary sinus increased in the LLTS group and
decreased in the control group (both p ¼ 0.04 for
comparison between groups) (Figure 4).
There were no signiﬁcant differences in any of the
cytokines measured at baseline between the 2 groups
(Table 3). Systemic TNF-a levels were suppressed
signiﬁcantly (2.3  0.3 pg/ml) compared with baseline
in the LLTS group but not in the control groupFIGURE 4 Effect of LLTS on AERP
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Both the right atrial (RA) and coronary sinus (CS) atrial effective
refractory period (AERP) increased in the low-level tragus stim-
ulation (LLTS) group and decreased in the control group.
TABLE 3 Cytokine Changes
LLTS Group (n ¼ 20) Control Group (n ¼ 20)
p Value*Baseline 1 h Baseline 1 h
Femoral vein TNF-a, pg/ml 9.2  4.8 6.9  4.4 7.6  3.0 6.8  3.0 0.006
IL-6, pg/ml 3.2  2.0 4.3  2.1 3.9  2.9 5.7  3.0 0.18
CRP, mg/l 9.8  10.2 7.9  8.2 6.6  3.4 6.2  3.9 0.001
IL-10, pg/ml 0.41  0.15 0.67  0.55 0.47  0.21 0.84  0.49 0.61
Coronary sinus TNF-a, pg/ml 9.1  5.5 7.4  5.0 7.8  3.3 6.3  2.8 0.83
IL-6, pg/ml 5.5  2.7 6.3  3.3 5.7  2.9 5.9  2.7 0.49
CRP, mg/l 8.3  4.7 9.7  9.5 8.0  5.4 7.1  3.6 0.27
IL-10, pg/ml 0.38  0.16 0.60  0.59 0.49  0.17 0.79  0.49 0.76
Values are mean  SD. *Comparison of the change in each parameter before and after LLTS or sham procedure
between the 2 groups.
CRP ¼ C-reactive protein; IL ¼ interleukin; LLTS ¼ low-level tragus stimulation; TNF ¼ tumor necrosis factor.
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872(between-group comparison p ¼ 0.006) (Central
Illustration). Importantly, the magnitude of decrease
in TNF-a levels by LLTS was comparable with
the difference between patients with active versus
inactive inﬂammatory diseases (17). Systemic CRP
levels decreased signiﬁcantly in the LLTS group
(1.9  1.4 ng/l) but not in the control group (between-
group comparison p ¼ 0.001) (Figure 5). Of note, the
decrease in TNF-a and CRP levels was similar in pa-
tients who did or did not undergo cardioversion. On
the contrary, no difference was observed in the cor-
onary sinus TNF-a or CRP levels between the 2
groups, indicating that the effect of LLTS was medi-
ated through the systemic circulation. Systemic and
coronary sinus IL-6 and IL-10 levels did not differ
signiﬁcantly between the 2 groups.
No major adverse events were noted in the study,
including no effect on blood pressure or heart rate
during stimulation. In 2 patients, a mild burn on theFIGURE 5 Effect of LLTS on Systemic CRP Levels
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There was a signiﬁcant decrease in systemic C-reactive protein
(CRP) levels compared with baseline in the low-level tragus
stimulation (LLTS) group, but not in the control group.right ear was observed at the site of the stimulating
electrode, which resolved with conservative mea-
sures. This adverse effect was not observed after
adjusting the tension of the metal clip delivering
LLTS.
Patients were followed at 1 month, 3 months, and
approximately every 3 months thereafter. Median
follow-up was 6 months (interquartile range: 4 to 10
months). During follow-up, 5 patients (25%) in each
group experienced recurrence of AF or atrial tachy-
cardia (p ¼ 0.93 by log-rank test).
DISCUSSION
In this study, transcutaneous electrical stimulation of
the auricular branch of the right vagus nerve at the
tragus suppressed AF and decreased inﬂammatory
cytokines. This proof-of-concept and ﬁrst-in-man
study raises the possibility that noninvasive auto-
nomic neuromodulation may be used to treat patients
with paroxysmal AF. Notably, the average stimulation
voltage used in this study (50% below the threshold
for slowing the sinus rate or AV conduction) was less
than the average discomfort threshold, suggesting
that this treatment modality may be tolerated by
ambulatory patients. Enhanced activity of the cardiac
autonomic nervous system (CANS) and AF create a
vicious cycle, in which high CANS activity can initiate
AF and AF further augments CANS activity (13). A
noninvasive neuromodulatory therapy such as LLTS
that can break this cycle in early AF may be useful
for a large population of AF patients. Additionally,
by shortening the AF duration and suppressing
the inﬂammatory process (Central Illustration), this
therapy may prevent AF from progressing to more
advanced stages, thereby decreasing the morbidities
associated with longstanding AF, such as stroke,
dementia, and HF.
ANTIARRHYTHMIC EFFECTS OF LLTS. CANS is a
neural network that controls the heart’s vascular,
contractile, and electrophysiological functions. The
neural signals in this network are integrated and
processed at the ganglionated plexi (GP), which may
contain hundreds to thousands of autonomic neurons
and are typically located in the epicardial fat pads
(18,19). Hyperactivity of the major atrial GP plays a
critical role in AF initiation and maintenance,
whereas ablating these GP provides additional bene-
ﬁts to the standard circumferential pulmonary vein
isolation procedure (20). Previous experimental
studies demonstrated that LLVNS and LLTS are anti-
adrenergic and anticholinergic (10,11,14,15). When
LLTS was delivered to the cranial end of the tran-
sected vagal trunk, all the antiarrhythmic effects of
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873LLTS disappeared, whereas LLVNS applied at the
distal end of the transected vagal trunks retained its
antiarrhythmic effects (9,15). Although LLVNS and
LLTS probably activate both the afferent and efferent
vagal ﬁbers, these observations suggest that the
efferent ﬁbers of the vagus nerves are crucial to the
antiarrhythmic effects. The seemingly “paradoxical”
anticholinergic effects of LLVNS and LLTS, which
require efferent vagal ﬁbers for their actions, are
mediated by inhibiting the activity of the major atrial
GP, as evidenced by direct neural recordings within
canine GP (10,12,13). Likewise, LLVNS decreases
the activity of the left stellate ganglion, the gateway
of sympathetic innervation to the heart (14). In
the present study, similar mechanisms are likely un-
derlying the antiarrhythmic effects of LLTS. The
anticholinergic effects prolong the AERP and the
antiadrenergic effects suppress the myocyte calcium
transients, leading to the inhibition of both re-entry
and triggered ﬁring (21). Moreover, suppressing
CANS activity also breaks the vicious cycle formed by
hyperactivity of the CANS and atrial remodeling (13).
Our results can be interpreted in light of the
currently accepted mechanism for AF initiation and
maintenance, which requires both a trigger and a
substrate (3). The trigger for paroxysmal AF often lies
in the pulmonary vein myocardium, whereas atrial
and autonomic remodeling provides the substrate for
AF to sustain once initiated (3). We have provided
evidence that LLTS modiﬁed the substrate for AF by
prolonging the AERP and AF cycle length. Although
this study offers no direct evidence that LLTS could
inhibit triggered activity, this effect has been dem-
onstrated in animal studies, in which LLVNS inhibited
induction of rapid ﬁring and AF from the pulmonary
veins (9,10). Moreover, the antiarrhythmic effects
of LLVNS and LLTS were very similar in various ani-
mal models of AF, including rapid atrial pacing,
acetylcholine-induced AF, and high-frequency stim-
ulation-induced triggered ﬁring (9,13,15). In this
study, we used widely accepted parameters, such as
AF duration, AF cycle length, and AERP. Although AF
inducibility lacks accuracy and its clinical signiﬁcance
is debatable (22), the favorable effects of LLTS on
other endpoints, such as AF duration and AERP, lend
credence to our results.
ANTI-INFLAMMATORY EFFECT OF LLTS. Our ﬁnd-
ings’ signiﬁcance is highlighted by substantial evi-
dence linking AF with inﬂammation (23–26). In a large
population-based study, CRP levels predicted both
the presence of AF at baseline and AF development
during follow-up, even after adjusting for other
known cardiovascular risk factors (23). Risk of AF
was also progressively higher with increasing CRPquartiles (23). In another case-control study, TNF-a
levels were signiﬁcantly increased in patients with AF
compared with control patients, and there was a
graded increase in TNF-a among patients with
paroxysmal, persistent, and permanent AF (25). In the
present study, it is noteworthy that blood levels of
inﬂammatory cytokines in both the LLTS and control
groups were elevated at baseline (27) and similar to
those reported in large population-based cohorts and
case-control studies (23,25). Moreover, the magnitude
of decrease in TNF-a and CRP levels by LLTS is
consistent with the difference between control and
pre-rheumatoid arthritis patients (27) as well as for
patients with active versus inactive inﬂammatory
diseases (17), suggesting a signiﬁcant biological ef-
fect. Extrapolating from the post-myocardial infarc-
tion literature, a decrease in CRP and/or TNF-a of a
similar magnitude to that observed in our study, if
sustained, would predict a lower incidence of recur-
rent cardiovascular events (28,29). Nonetheless,
given that the sustainability of inﬂammatory cytokine
reduction and the long-term effects of LLTS remain
unknown, these results should be interpreted
cautiously.
More than 80% of the nerve ﬁbers in the vagal
trunks are afferent vagal ﬁbers carrying neural
input from nearly the entire body, and the tonic ac-
tivity of the vagus nerves is essential to maintain
immune homeostasis (30). Our results are consistent
with the recently recognized anti-inﬂammatory
properties of the vagus nerve (30,31). Stimulation of
the cholinergic anti-inﬂammatory pathway, which is
composed of efferent vagus nerve signals, leads to
acetylcholine-dependent activation of the alpha-7
nicotinic acetylcholine receptor subunit on mono-
cytes and macrophages, resulting in reduced pro-
duction of the inﬂammatory cytokines TNF-a, IL-1b,
and IL-6, but not IL-10 (31,32). Reduction in inﬂam-
matory markers with vagus nerve stimulation was
also observed in a canine model of HF (33). The
ﬁnding that LLTS suppresses systemic but not coro-
nary sinus levels of TNF-a and CRP suggests that
the reduction of inﬂammatory cytokines was the
result of activation of the cholinergic anti-
inﬂammatory pathway and not just a local cardiac
vagal effect. The cholinergic anti-inﬂammatory
pathway involves efferent vagus nerve ﬁbers, trav-
eling to the spleen through the celiac ganglion and
the splenic nerve to inhibit inﬂammatory responses
(30). If the anti-inﬂammatory effects observed resul-
ted from a local cardiac effect, the coronary sinus
cytokine levels would have decreased before the sys-
temic cytokine levels did. Importantly, we have pro-
vided evidence that the cholinergic anti-inﬂammatory
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
AF and associated inﬂammatory cytokines can be
suppressed by delivering low-level transcutaneous
vagus nerve stimulation at the tragus.
TRANSLATIONAL OUTLOOK: Further studies are
needed to explore the safety, efﬁcacy and long-term
outcomes of nonpharmacologic, nonablative neuro-
modulatory therapy for patients with paroxysmal AF.
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874pathway can be activated without heart rate slowing,
consistent with a previous experimental study, which
demonstrated that transcutaneous vagus nerve stim-
ulation inhibited inﬂammatory cytokine production
in mice with endotoxemia (34).
CLINICAL IMPLICATIONS. In this study, we demon-
strated that neuromodulation by LLTS is a promising,
noninvasive therapy to treat AF and AF-related in-
ﬂammation. Given the recently demonstrated bene-
ﬁcial effects of vagus nerve stimulation in patients
with HF (8,35), neuromodulation may provide a
means of treating patients with both HF and AF with a
single treatment modality. Moreover, these results
may provide the basis to potentially expand the
therapeutic targets of this treatment modality into
other inﬂammatory conditions, including rheumatoid
arthritis and systemic lupus erythematosus (30). In
the present study, the stimulation voltage (50% below
the cardiac threshold) was lower than the discomfort
threshold in the average patient. Importantly, LLTS
with the stimulation strength 80% below the cardiac
threshold exerted similar antiarrhythmic effects as
50% below the cardiac threshold (15), indicating that
this noninvasive approach can be tolerated by ambu-
latory patients. Moreover, transcutaneous stimula-
tion of the auricular branch of the vagus nerve in
patients with epilepsy was safe and tolerable in a
recent pilot study (36).
STUDY LIMITATIONS. The optimal stimulation pa-
rameters for LLTS have not been determined. In this
study we used 20 Hz based on our previous animal
experience (9–12). Further studies are necessary to
evaluate the shortest time period and the lowest
stimulation strength of LLTS that would have a
beneﬁcial effect. Intermittent stimulation may be
more efﬁcacious than continuous stimulation, based
on recent experimental evidence (37). Although any
LLTS-caused discomfort may have been masked by
general anesthesia, the average stimulation level
(<50% lower than the voltage threshold) was lower
than the average discomfort threshold. In every pa-
tient, the discomfort threshold was higher than theLLTS voltage level. Thus, it is unlikely that discomfort
is a major contributing factor to the effect of LLTS.
There was a trend toward an increased prevalence of
diabetes in the control group, which appears to be
clinically signiﬁcant. However, the 2 groups were
otherwise well matched; thus, it is unlikely that these
small differences inﬂuenced the results. In this study,
we examined the acute effects of LLTS; further trials
are warranted to evaluate the long-term clinical
importance of our ﬁndings.
CONCLUSIONS
In this study, we demonstrated for the ﬁrst time in
humans that the duration and inducibility of AF, as
well as inﬂammatory cytokines were suppressed
noninvasively by low-level transcutaneous electrical
stimulation of the auricular branch of the vagus nerve
at the tragus. Our results support the notion that
autonomic neuromodulation may emerge as an
alternative nonpharmacological, nonablative modal-
ity to treat paroxysmal AF. Further studies in ambu-
latory patients are warranted.
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